Clinical Trial Update: Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating adipose-derived mesenchymal cell treatment for lung transplant rejection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Transplant Rejection

Drugs mentioned

• adipose-derived mesenchymal cells

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Lung Transplant Rejection | Phase 1, Phase 2 | Status: UNKNOWN